Franz Zehentmayr

19PUBLICATIONS
14CO-AUTHORS
Radiation therapyPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Formal methods for softwareMedical virology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (19)

|Jun 17, 2026
Computed tomography monitoring of small lung nodules: finding the right balance.

|Feb 09, 2026
Lung cancer survivorship: natural language processing for automated abstraction of follow-up computed tomography indication.

Brane Grambozov, Elvis Ruznic, Franz Zehentmayr

|Dec 30, 2025
MLR and dMLR Predict Locoregional Control and Progression-Free Survival in Unresectable NSCLC Stage III Patients: Results from the Austrian Radio-Oncological Lung Cancer Study Association Registry (ALLSTAR).

Alexandra Hochreiter, Markus Stana, Marisa Klebermass

|Dec 24, 2025
Durvalumab Is Associated with Prolonged Progression-Free Survival, While Concomitant Chemoradiotherapy May Improve Both Locoregional and Local Control in Elderly Patients with Unresectable NSCLC Stage III: Subanalysis of the Austrian Radio-Oncological Lung Cancer Study Association Registry (ALLSTAR).

Franz Zehentmayr, Josef Karner, Markus Stana

|Aug 28, 2025
Delta Changes in [18F]FDG PET/CT Parameters Can Prognosticate Clinical Outcomes in Recurrent NSCLC Patients Who Have Undergone Reirradiation-Chemoimmunotherapy.

Brane Grambozov, Nazanin Zamani-Siahkali, Markus Stana

|May 14, 2025
Durvalumab Prolongs Overall Survival, Whereas Radiation Dose Escalation > 66 Gy Might Improve Long-Term Local Control in Unresectable NSCLC Stage III: Updated Analysis of the Austrian Radio-Oncological Lung Cancer Study Association Registry (ALLSTAR).

Franz Zehentmayr, Petra Feurstein, Elvis Ruznic

Pageof 4

Frequent Collaborators

10 joint publications

Elvis Ruznic

7 joint publications

Markus Stana

5 joint publications

Brane Grambozov

3 joint publications

Ayurzana Purevdorj